Amphastar Pharmaceuticals マネジメント

マネジメント基準チェック /34

Amphastar Pharmaceuticalsの CEO はJack Zhangで、 Jan1996年に任命され、の在任期間は 28.83年です。の年間総報酬は$ 7.72Mで、 11.6%給与と88.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の4.81%を直接所有しており、その価値は€ 98.55M 。経営陣と取締役会の平均在任期間はそれぞれ11年と5.4年です。

主要情報

Jack Zhang

最高経営責任者

US$7.7m

報酬総額

CEO給与比率	11.6%
CEO在任期間	28.8yrs
CEOの所有権	4.8%
経営陣の平均在職期間	11yrs
取締役会の平均在任期間	5.4yrs

経営陣の近況

Recent updates

CEO報酬分析

Amphastar Pharmaceuticals の収益と比較して、Jack Zhang の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	US$158m
Jun 30 2024	n/a	n/a	US$167m
Mar 31 2024	n/a	n/a	US$155m
Dec 31 2023	US$8m	US$898k	US$138m
Sep 30 2023	n/a	n/a	US$135m
Jun 30 2023	n/a	n/a	US$102m
Mar 31 2023	n/a	n/a	US$93m
Dec 31 2022	US$7m	US$1m	US$91m
Sep 30 2022	n/a	n/a	US$77m
Jun 30 2022	n/a	n/a	US$91m
Mar 31 2022	n/a	n/a	US$81m
Dec 31 2021	US$7m	US$898k	US$62m
Sep 30 2021	n/a	n/a	US$36m
Jun 30 2021	n/a	n/a	US$10m
Mar 31 2021	n/a	n/a	US$2m
Dec 31 2020	US$6m	US$898k	US$1m
Sep 30 2020	n/a	n/a	US$7m
Jun 30 2020	n/a	n/a	US$4m
Mar 31 2020	n/a	n/a	US$52m
Dec 31 2019	US$6m	US$898k	US$49m
Sep 30 2019	n/a	n/a	US$52m
Jun 30 2019	n/a	n/a	US$53m
Mar 31 2019	n/a	n/a	US$2m
Dec 31 2018	US$6m	US$1m	-US$6m
Sep 30 2018	n/a	n/a	-US$7m
Jun 30 2018	n/a	n/a	-US$9m
Mar 31 2018	n/a	n/a	-US$4m
Dec 31 2017	US$6m	US$880k	US$4m

報酬と市場: Jackの総報酬 ($USD 7.72M ) は、 German市場 ($USD 1.65M ) の同規模の企業の平均を上回っています。

報酬と収益: Jackの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jack Zhang (77 yo)

28.8yrs

在職期間

US$7,722,768

報酬

Dr. Yongfeng Zhang, also known as Jack, Ph D., has been President at Amphastar Pharmaceuticals, Inc. since April 10, 2020. He co-founded Amphastar Pharmaceuticals in 1996 and has been its Chief Executive O...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ziping Luo	Chairman of the Board	28.8yrs	US$3.77m	2.12% € 43.5m
Yongfeng Zhang	Co-founder	28.8yrs	US$7.72m	4.81% € 98.6m
William Peters	CFO, Executive VP of Finance	10.6yrs	US$2.89m	0.076% € 1.6m
Jacob Liawatidewi	Executive VP of Sales	11.4yrs	US$1.78m	0.097% € 2.0m
Rong Zhou	Senior EVP of Production & EVP of Scientific Affairs	9.4yrs	US$2.03m	0.39% € 8.0m
Dan Dischner	Senior Vice President of Human Resources & Corporate Communication	2.3yrs	データなし	データなし
Tony Marrs	Executive VP of Regulatory Affairs & Clinical Operations	no data	データなし	データなし

11.0yrs

平均在職期間

65yo

平均年齢

経験豊富な経営陣: 29Aの経営陣は経験豊富で経験豊富です（平均在職期間は11年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Ziping Luo	Chairman of the Board	28.8yrs	US$3.77m	2.12% € 43.5m
Yongfeng Zhang	Co-founder	28.8yrs	US$7.72m	4.81% € 98.6m
William Peters	CFO, Executive VP of Finance	2.3yrs	US$2.89m	0.076% € 1.6m
Jacob Liawatidewi	Executive VP of Sales	2.3yrs	US$1.78m	0.097% € 2.0m
Richard Prins	Lead Independent Director	22.8yrs	US$362.00k	0.057% € 1.2m
Gayle Deflin	Independent Director	3.4yrs	US$330.00k	0% € 0
Chen Yang	Member of Scientific Advisory Board	no data	データなし	データなし
Paul White	Member of Scientific Advisory Board	no data	データなし	データなし
Gordon Treweek	Member of Scientific Advisory Board	no data	データなし	データなし
Herschel Rabitz	Member of Scientific Advisory Board	no data	データなし	データなし
Richard Porter	Member of Scientific Advisory Board	no data	データなし	データなし
Diane Gerst	Independent Director	5.4yrs	US$314.70k	0.027% € 547.2k

5.4yrs

平均在職期間

65.5yo

平均年齢

経験豊富なボード: 29Aの取締役会は経験豊富であると考えられます ( 5.4年の平均在任期間)。

Amphastar Pharmaceuticals マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as Director

Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024

Insider recently sold €543k worth of stock

Lead Independent Director recently sold €245k worth of stock

Insider recently sold €668k worth of stock

Insider recently sold €291k worth of stock

Recent updates

New minor risk - Insider selling

Third quarter 2024 earnings released: EPS: US$0.83 (vs US$1.01 in 3Q 2023)

Amphastar Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024

New minor risk - Insider selling

Second quarter 2024 earnings released: EPS: US$0.78 (vs US$0.54 in 2Q 2023)

Amphastar Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as Director

Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol

First quarter 2024 earnings released: EPS: US$0.90 (vs US$0.54 in 1Q 2023)

Amphastar Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024

Insider recently sold €543k worth of stock

Investor sentiment deteriorates as stock falls 15%

Full year 2023 earnings released: EPS: US$2.85 (vs US$1.88 in FY 2022)

Amphastar Pharmaceuticals, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2023

Amphastar Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Investor sentiment deteriorates as stock falls 17%

Lead Independent Director recently sold €245k worth of stock

Investor sentiment improves as stock rises 24%

Third quarter 2023 earnings released: EPS: US$1.01 (vs US$0.33 in 3Q 2022)

Amphastar Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Insider recently sold €668k worth of stock

Investor sentiment deteriorates as stock falls 18%

New major risk - Financial position

Second quarter 2023 earnings released: EPS: US$0.54 (vs US$0.35 in 2Q 2022)

Amphastar Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Investor sentiment improves as stock rises 16%

New minor risk - Share price stability

Investor sentiment improves as stock rises 16%

Insider recently sold €291k worth of stock

First quarter 2023 earnings released: EPS: US$0.54 (vs US$0.50 in 1Q 2022)

Amphastar Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 09, 2023

Investor sentiment deteriorates as stock falls 17%

Full year 2022 earnings released: EPS: US$1.88 (vs US$1.30 in FY 2021)

Third quarter 2022 earnings released: EPS: US$0.33 (vs US$0.61 in 3Q 2021)

Amphastar Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: US$0.35 (vs US$0.16 in 2Q 2021)

Amphastar Pharmaceuticals, Inc. Announces Executive Changes

Amphastar Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Investor sentiment improved over the past week

Chairman of the Board recently sold €3.5m worth of stock

First quarter 2022 earnings released: EPS: US$0.50 (vs US$0.11 in 1Q 2021)

Amphastar Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 09, 2022

Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS US$0.61 (vs US$0.083 in 3Q 2020)

Independent Director David Maris has left the company

Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH) entered into a share purchase agreement to acquire the remaining 15% stake in Amphastar Nanjing Pharmaceuticals, Co., Ltd., from Applied Physics & Chemistry Laboratories, Inc., Bill Zhang and Chongqing Zhang for $22.5 million.

Second quarter 2021 earnings released: EPS US$0.16 (vs US$0.004 loss in 2Q 2020)

Insider recently sold €76k worth of stock

Insider recently sold €73k worth of stock

First quarter 2021 earnings released: EPS US$0.11 (vs US$0.085 in 1Q 2020)

Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Morphine Sulfate Injection

Full year 2020 earnings released: EPS US$0.03 (vs US$1.04 in FY 2019)

Amphastar Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 15, 2021

New 90-day low: €14.50

Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Index

Amphastar Announces Approval for Glucagon for Injection Kit, 1mg

New 90-day low: €15.00

Revenue misses expectations

Third quarter 2020 earnings released: EPS US$0.083

Amphastar Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 06, 2020

Amphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate Injection

New 90-day low: €15.80

New 90-day low - €16.50

Earnings released

Amphastar Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 06, 2020

Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Index

マネジメント基準チェック /34